Output 20 Pages

Automating PSUR/PBRER: A Technical Guide

How ArcaScience automates ICH E2C(R2)-compliant Periodic Safety Update Reports with integrated data intelligence, signal detection synthesis, and quantitative benefit-risk evaluation—reducing preparation time from months to weeks while maintaining complete regulatory traceability.

Download Full Whitepaper

Executive Summary

Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs) represent one of the most resource-intensive regulatory obligations in pharmacovigilance. A single PSUR can consume 3-6 months of pharmacovigilance team effort, requiring manual compilation of adverse event data from global safety databases, systematic literature review, signal evaluation, and comprehensive benefit-risk assessment.

ArcaScience's automation platform integrates data from global safety databases (FAERS, EudraVigilance, VigiBase), literature monitoring systems (PubMed, Embase), clinical trial registries, and real-world evidence sources to generate ICH E2C(R2)-compliant PSUR/PBRER documents in a fraction of the time. The platform maintains complete data traceability and regulatory audit trails while embedding quantitative benefit-risk analysis directly into each report section.

This technical guide walks through the architecture, methodology, and validation approach that enables regulatory-grade document generation with 75% reduction in preparation time, 100% ICH E2C(R2) section coverage, and seamless eCTD Module 2.7 formatting for direct regulatory submission.

Key Takeaways

ICH E2C(R2) Alignment

Every PSUR section—from executive summary through appendices—is mapped directly to ICH E2C(R2) regulatory requirements. Automated compliance checks ensure no required elements are missing before submission.

Automated Data Integration

Continuous ingestion from FAERS, EudraVigilance, VigiBase, company safety databases, and sponsor-specific data warehouses. Data is normalized, deduplicated, and harmonized to MedDRA terminology automatically.

Signal Detection Synthesis

Automated disproportionality analysis (PRR, ROR, MGPS, BCPNN) with AI-augmented signal evaluation. Generates signal narratives with complete supporting evidence tables and statistical workbooks.

Literature Monitoring

Continuous PubMed and Embase screening with AI-powered relevance scoring. Literature results are automatically extracted, categorized, and integrated into PSUR section narratives with full citation management.

Benefit-Risk Evaluation

Quantitative benefit-risk analysis embedded directly into the PSUR Integrated Benefit-Risk Analysis section. BRAT framework value trees, effects tables, and sensitivity analyses generated automatically.

Submission-Ready Output

Documents are formatted for eCTD Module 2.7 with automated table of contents, figure/table numbering, and cross-references. Direct export to regulatory portal submission formats (FDA Gateway, EMA Gateway).

What's Inside

This 20-page technical guide provides a complete walkthrough of PSUR/PBRER automation methodology:

1

The PSUR/PBRER Regulatory Landscape

Evolution from PSUR to PBRER, ICH E2C(R2) requirements, regional variations, and the business case for automation.

2

ICH E2C(R2) Requirements and Structure

Detailed breakdown of all 19 PBRER sections, regulatory expectations, and how ArcaScience maps to each requirement.

3

Data Sources and Integration Architecture

How the platform ingests from FAERS, EudraVigilance, VigiBase, sponsor databases, and clinical trial data with full lineage tracking.

4

Automated Signal Evaluation for PSURs

Disproportionality methods (PRR, ROR, MGPS, BCPNN), threshold tuning, false discovery rate control, and narrative generation.

5

Literature Monitoring and Evidence Synthesis

Continuous literature screening, relevance classification, full-text extraction, and automated citation management.

6

Benefit-Risk Evaluation Integration

Embedding BRAT framework analysis into PBRER Section 16: Integrated Benefit-Risk Analysis for Approved Indications.

7

Document Generation and Quality Assurance

Template engine architecture, automated QC checks, medical writer review workflow, and version control.

8

eCTD Formatting and Submission Workflow

Module 2.7 packaging, automated table/figure numbering, cross-reference validation, and direct export to FDA/EMA Gateway formats.

Sample Content

Preview two chapters from the whitepaper:

Chapter 1: The PSUR/PBRER Regulatory Landscape

Periodic Safety Update Reports were introduced by the International Council for Harmonisation (ICH) in 1996 as a standardized format for post-approval safety reporting. The guideline underwent significant revision in 2012 with ICH E2C(R2), which reframed the document as a Periodic Benefit-Risk Evaluation Report (PBRER)—emphasizing not just adverse event cataloging, but comprehensive benefit-risk assessment.

The transition from PSUR to PBRER reflected a fundamental shift in regulatory thinking: safety signals must be evaluated in the context of therapeutic benefit, patient population characteristics, and availability of alternative treatments. This change increased both the scientific rigor and operational burden of periodic reporting.

A typical PSUR/PBRER for a marketed product requires:

  • Manual review of 5,000-50,000 adverse event reports from global databases
  • Systematic literature screening of 200-2,000 publications
  • Signal detection analysis across multiple therapeutic areas and geographies
  • Integration of clinical trial safety data, real-world evidence, and non-clinical findings
  • Comprehensive benefit-risk narrative with quantitative or semi-quantitative analysis
  • Preparation of 100-300 page documents with 20-50 appendices

This work typically consumes 3-6 months of effort from multidisciplinary teams including pharmacovigilance scientists, medical writers, statisticians, and medical reviewers. For companies with large portfolios, the resource burden can become unsustainable—particularly when combined with other pharmacovigilance obligations like Development Safety Update Reports (DSURs), Risk Management Plans (RMPs), and signal management activities.

The business case for automation: ArcaScience's platform enables 75% reduction in PSUR preparation time while improving consistency, reducing human error, and maintaining complete audit trails. This frees senior pharmacovigilance staff to focus on strategic signal evaluation and regulatory strategy rather than document assembly.

Chapter 3: Data Sources and Integration Architecture

Automated PSUR generation depends on robust, real-time data integration from multiple heterogeneous sources. ArcaScience's data pipeline ingests safety data from:

Global Safety Databases

  • FDA FAERS: 15+ million adverse event reports, quarterly releases, normalized to MedDRA
  • EMA EudraVigilance: 20+ million reports from EU member states, real-time access via EVDAS
  • WHO VigiBase: 25+ million reports from 140+ countries, accessed via VigiLyze API
  • PMDA (Japan), Health Canada, MHRA (UK): Regional databases integrated on rolling basis
  • Sponsor safety databases: Oracle Argus, ArisGlobal LifeSphere, Veeva Vault SafetyDocs via HL7 ICSR feeds

Literature and Publication Sources

  • PubMed/MEDLINE: 35+ million biomedical citations, daily updates via E-utilities API
  • Embase: 40+ million records including conference abstracts, accessed via Elsevier API
  • ClinicalTrials.gov: Trial results data for efficacy/safety comparison
  • Regulatory agency communications: FDA Drug Safety Communications, EMA safety referrals

Data Harmonization Pipeline

Raw data from these sources undergoes a four-stage normalization process:

  1. Deduplication: Fuzzy matching on patient demographics, event dates, reporter information to identify duplicates across databases
  2. MedDRA standardization: All adverse events mapped to consistent MedDRA version (currently 26.0), with automatic updates when new versions release
  3. Data quality scoring: Completeness, recency, source reliability used to weight reports in signal detection
  4. Lineage tracking: Every data point maintains full provenance chain for regulatory audit trails

This architecture enables near-real-time PSUR data queries while maintaining the data integrity and traceability required for regulatory submissions. Chapter 3 includes detailed data flow diagrams, API specifications, and validation test cases used in platform development.

Impact on PSUR Preparation

Real-world performance metrics from production deployments

0%

Reduction in PSUR preparation time from initial data lock to final submission-ready document

0%

ICH E2C(R2) section coverage with automated compliance validation and missing element detection

0

Global safety databases integrated for comprehensive adverse event coverage and signal detection

Related Whitepapers

BRAT Framework
18 pages

BRAT Framework Implementation

Step-by-step guide to automating the Benefit-Risk Action Team framework for regulatory submissions.

Learn More
Signal Detection
14 pages

Signal Detection at Scale

Technical deep-dive on disproportionality analysis methods and AI-augmented signal identification.

Learn More
The ArcaScience Methodology
24 pages

The ArcaScience Methodology

Comprehensive overview of the platform's scientific foundation, data architecture, and AI model taxonomy.

Learn More

Download the Full Whitepaper

Get the complete 20-page technical guide to PSUR/PBRER automation with detailed methodology, validation data, and implementation case studies.

Corporate email required. Your information will be used in accordance with our privacy policy.

See PSUR Automation in Action

Schedule a live demonstration to see how ArcaScience generates ICH E2C(R2)-compliant PSURs from your own safety data, or discuss custom deployment for your pharmacovigilance team.

Request a Demo Explore Platform Outputs